Biomarkers are increasingly used for diagnosis and treatment of transplant-related complications including the first biomarker-driven interventional trials of acute graft-versus-host disease (GvHD). In contrast, the development of biomarkers of chronic GvHD (cGvHD) has lagged behind due to a broader variety of manifestations, overlap with acute GvHD, a greater variation in time to onset and maximum severity, and lack of sufficient patient numbers within prospective trials. An international workshop organized by a North-American and European consortium was held in Marseille in March 2017 with the goal to discuss strategies for future biomarker development to guide cGvHD therapy. As a result of this meeting, two areas were prioritized: the development of prognostic biomarkers for subsequent onset of moderate/severe cGvHD, and in parallel, the development of qualified clinical-grade assays for biomarker quantification. The most promising prognostic serum biomarkers are CXCL9, ST2, matrix metalloproteinase-3, osteopontin, CXCL10, CXCL11, and CD163. Urineproteomics and cellular subsets (CD4 + T-cell subsets, NK cell subsets, and CD19 + CD21 low B cells) represent additional potential prognostic biomarkers of cGvHD. A joint effort is required to verify the results of numerous exploratory trials before any of the potential candidates is ready for validation and subsequent clinical application.
Introduction
Biomarkers are increasingly considered in the treatment of malignant diseases and are currently being validated with regards to outcome prediction in patients with acute graftversus-host disease (aGvHD) [1, 2] . The first trials have been launched where biomarker assessment determines aGvHD immunosuppressive interventions through the Blood and Marrow Transplant Clinical Trials Network (BMTCTN protocol 1501) [2] . Despite the increasing incidence of chronic GvHD (cGvHD) [3] , the identification of biomarkers in cGvHD has lagged behind for several reasons, including (a) varied impact on recipient organs, which differentially influences the prognosis including overlap with aGvHD, (b) a much longer time frame in onset and course of the disease and (c) a lack of sufficient patient numbers within multicenter trials to adjust for the heterogeneity of patients with cGvHD. The National Institutes of Health (NIH) consensus on cGvHD in 2005 provided the basic principles for diagnostic criteria and biomarker development [4, 5] . These consensus recommendations were updated in 2014 [6, 7] defining the steps for exploration (identification of potential biomarker candidates) and verification of potential biomarkers (replication in independent patient cohorts including test practicability and stability) prior to qualification for clinical application. Currently, the development of biomarkers in cGvHD has not yet passed the verification phase mainly due to three major reasons. First, the evaluated biomarkers differed in trials due to technical reasons as well as selection of different probes and time points (before or after start of immunosuppression) making it currently impossible to select an optimal biomarker panel for qualification. Second, cGvHD biomarker studies try to predict the development of any cGvHD without recognizing subgroups that may have different pathogenesis [8] . Third, heterogeneity in laboratory assays not approved for clinical use could cause significant variations in biomarker verification trials. For example, C-X-C chemokine motif ligand 9 (CXCL9) has been identified within several cohorts [9, 10] as the most sensitive marker, while within other cohorts, CXCL10 performed better compared to CXCL9 [11, 12] . An additional issue relates to the need for prospective real-time documentation of cGvHD within verification trials. This is important, since any retrospective documentation bears the risk of insufficient clinical details or possible retrospective bias in the disease course interpretation. In summary, currently some promising serum/plasma biomarkers [10, 11] and cellular subpopulations [13] have been identified that should be studied in verification trials. Urine proteomics may be a potential option [14] while gene expression assays require further exploration. Besides HLA-typing, none of the genetic markers reached an association level sufficient to be used as a biomarker of cGvHD in a clinical setting [15] .
To further support collaborative efforts in cGvHD biomarker development, an international workshop was organized by a North-American and European consortium, which was held in Marseille on March 24 and 25, 2017. The workshop included a systematic review of current evidence. Participants sought to develop strategies for future joint efforts toward qualified biomarker development for guidance of cGvHD therapy. The workshop summary is presented here.
Consideration of clinical heterogeneity
Development of biomarkers in cGvHD may require some specific consideration with regard to the sensitivity and specificity in subgroups with different clinical characteristics. Any biomarker should be carefully evaluated during the verification phase with regard to cofactors that may affect biomarker levels. These factors, for instance, can include donor source, intensity of the preparative regimen, or the use of total body irradiation [6, 11] . The inclusion of control patients after autologous peripheral blood stem cell transplantation and time-matched patients after allogeneic hematopoietic stem cell transplantation (alloHSCT) without GvHD may help to adjust for non-cGvHD confounding factors. Moreover, presence and impact of specific organ patterns of cGvHD should be evaluated. An additional issue is how to better quantify the contribution of concurrent aGvHD features (called overlap-subtype of cGvHD), which may represent a different pathobiology compared to classical cGvHD with subsequent misattribution of late aGvHD biomarkers to cGvHD. Additional crucial issues are the impact of systemic immunosuppression and concurrent infections on biomarker levels, as, for instance, steroids suppress soluble B-cell activating factor of the tumor necrosis factor family (sBAFF) [16] while viral infections with herpes class viruses like cytomegalovirus may induce CXCL10 expression [17] .
Development of a clinical-grade assay and prerequisites of validation trials
A major obstacle is that aside from platelets [18] [19] [20] and lymphocyte counts [21] none of the assays currently applied in cGvHD studies has been approved for clinical use. Therefore, qualification of a biomarker requires in parallel development of a verified diagnostic tool as outlined in the 2014 NIH consensus on cGvHD [6] . For assessing the impact of numerous covariates summarized by Paczesny et al. [6] and confirmed by Kariminia et al. [11] , standardized documentation within future biomarker trials is required that includes time after transplantation, stem cell source, immune reconstitution, prior acute GvHD, intensity of immunosuppression before and at the time of assessment, and presence of infections. Sampling of biomarker probes requires application of standard operating procedures (SOPs) including the collection, transportation, storage, and processing of samples. Biomarker terminology also needs to be standardized. To harmonize with concepts used by the US Food and Drug Administration [22] , the following terminology was proposed in the context of cGvHD: prognostic biomarkers aim to provide information about the risk for subsequent cGvHD while predictive biomarkers are applied to predict the course of cGvHD at diagnosis or at later time points. Diagnostic biomarkers are used to confirm the diagnosis of cGvHD [6] .
In order to obtain an NIH-qualified biomarker for clinical application, two issues have to be considered: (1) assay qualification (which may be performed on a retrospective cohort) and (2) clinical qualification in prospective cohorts and assessment in utility trials. As already mentioned, validated assays with standardized SOPs must be used as well to ensure for reproducibility in the qualification studies. To address clinical qualification, the workshop participants agreed on the need for a prospective multicenter cohort including prospective documentation of clinical data as previously outlined in ref. [6] as well as standardized sampling in newly diagnosed, untreated patients with cGvHD. Potential markers to be evaluated are outlined below.
Identification of prognostic biomarkers
Prognostic biomarkers predict the subsequent development of cGvHD. The group discussed that it is most important to prognose the development of moderate-severe forms of cGvHD to target for prevention/preemptive therapy, since occurrence of mild cGvHD does not require systemic immunosuppression and has been associated with superior overall survival due to a graft-versus-tumor effect and prevention of mild cGvHD could paradoxically worsen patients' outcomes [19, 23] . Therefore, any prognostic biomarker should have a high negative predictive value to avoid inappropriately prolonged immunosuppression, while an impaired positive predictive value seems to be less problematic because at worst a patient would start treatment of cGvHD once symptoms are presented, which is currently standard clinical practice. Potential serum candidates are CXCL9 [24] , ST2, matrix metalloproteinase-3, osteopontin [10] , CXCL10, and CXCL11 [24, 25] and CD163 in plasma [26] . Urine proteomics may be an additional prognostic approach since it showed a sensitivity and specificity of 84 and 78%, respectively, within 2 separate European cohorts but failed to correlate with a current cGvHD US cohort (Lee, S.J. verbal communication). With regard to cellular markers, the expansion of CD4 + CD45RA + T cell as well as CD19 + CD21 low B cells on day 100 after alloHSCT may serve as prognostic biomarkers of subsequent development of cGvHD [13, 25, 27] . Additional cellular subsets including regulatory T cells, regulatory natural killer (NK) cells, and NKT cells are currently being explored but require further evaluation [8, 28] . With regard to genetic biomarkers, a number of candidates of prognostic polymorphisms were identified in small-and medium-sized cohorts but failed to be consistently replicable in larger cohorts underlining the crucial role of sufficiently powered replication sets including different donor types and graft sources [15] . Clinical trials evaluating prognostic, diagnostic, and predictive markers being actively considered are shown in Table 1 .
Identification of diagnostic biomarkers
While cGvHD is usually easily diagnosed based on clinical and histological criteria [7, 29, 30] , certain clinical conditions may benefit from biomarker measurements. For example, a considerable number of patients may be thought to have cGvHD but do not show diagnostic signs [7] and require histopathological confirmation, which is often invasive (liver, lung) [29, 31] , difficult to obtain and interpret (eye), and may delay treatment [32] . In addition, some pediatric evaluations are particularly challenging when testing cannot be performed (i.e., pulmonary function testing and Schirmer's test) and histopathology requires general anesthesia. Therefore, an easy to assess biomarker would be a significant advantage in clinical care by speeding up the diagnostic evaluation, providing additional certainty of the diagnosis, and may furthermore serve a quality-control purpose for inclusion in clinical trials. Last but not least, organ-specific biomarkers may help to differentiate active organ involvement caused by GvHD from other organ impairments caused by comorbidities like preexisting chronic obstructive pulmonary disease. A number of serum/plasma candidate proteins have been explored as diagnostic biomarkers of cGvHD. CXCL9, CXCL10, and sBAFF have been most frequently associated with the onset of cGvHD [9-11, 33, 34] , with anti-LG3, ST2, matrix metalloproteinase 3, and osteopontin being additional candidates [10, 11] . With regard to cellular biomarkers, a high proportion of CD19 +
CD21
low B cells and CD4 + T-cell subsets have been associated with diagnosis of cGvHD [13, 35] while within a different cohort the lack of CXCR3 + (ligand for CXCL9 &10) CD56 bright NK cells correlated with diagnosis of cGvHD with CXCR3 +
CD4
+ T cells being an additional cellular marker of interest [11] while other cellular subsets like regulatory T cells and their ratio to effector T cells require further evaluation. [8] With regard to potential organ-specific biomarkers, very high sBAFF levels and expansion of CD19 + CD21 low B cells have been associated with lung manifestations both at first onset of bronchiolitis obliterans syndrome as well as in ongoing pulmonary disease [35] . In aGvHD, elafin is a specific marker for skin involvement [36, 37] , and Reg3alpha indicates gastrointestinal manifestations and could indicate overlap cGvHD [38] . Currently, candidate organ-specific serum markers for oral or ocular GvHD are lacking, but saliva [39] or tear proteomics [40] have been explored.
Identification of predictive biomarkers
Limited data are available from exploratory studies showing that normalization of sBAFF and regeneration of CD19 + CD20 + CD27 − B cells after exposure to rituximab are associated with response to B-cell depletion [41, 42] and extracorporeal photopheresis (ECP) [43] . In addition, a decline of CD19 + CD21 low B cells has been demonstrated in ECP responders [44] . Moreover, persisting elevation of CXCL10, CXCL9, and ST2 has been associated with active cGvHD although additional studies are needed [33] . An additional aspect of predictive biomarkers is the differentiation of non-reversible inactive lesions of cGvHD from active disease, which may be relevant during the course of disease.
Additional biomarkers have been evaluated in different indications recently summarized in ref. [6] and further insight into the pathophysiology of cGvHD was recently summarized in ref. [8] .
Future collaboration
Advancement of candidate biomarkers for cGVHD requires international collaboration. The first level of NIH-defined qualification requires development and application of qualified assays to guarantee that biomarkers' measurement is consistent between laboratories. In parallel, the development of certified assays in cooperation with industrial partners is of crucial relevance, since none of the currently applied methods have been certified for clinical application, which is the prerequisite for biomarker qualification within clinical trials. Since it is unlikely that a single biomarker will cover all aspects of cGvHD, it will be important to define a panel of biomarkers before developing clinicalgrade assays as multiplex enzyme-linked immunosorbent assays are technically challenging and the development of assays using direct detection of proteins or protein fragments requires a predefined panel to be cost effective. While assay qualification may be performed on already existing D diagnostic, Prog1 prognostic measured at days 80-100, Prog2 prognostic measured in donor product at the time of transplant, Prog3 prognostic measured up to 55 days before diagnosis, R response to therapy, Pre predictive biomarker, Pl plasma, C cells, R RNA, U urine, RT recipient after BMT, Do donor cell product at the time of BMT a Source of the biomarker samples, clinical qualification requires prospective sampling and data collection. As first steps, the international participants agreed that prospective biomarker trials within the US cGvHD-consortium, the Canadian pediatric ABLE-consortium, and the German-Austrian-Swiss GvHD consortium should be initiated. At a minimum, these biomarker trials should include standardized sample preparation, storage, the exchange of reference samples and protocols between the centers to test the robustness and reproducibility of assays followed by a prospective cohort study that includes internal standards and parallel measurements conducted in all participating laboratories. The verification and qualification of candidate biomarkers in pediatric populations is highly relevant since this is a notoriously underrepresented population within clinical trials and adult data may not be extrapolated to the pediatric population. In summary, a joint effort is required to verify the results of numerous exploratory trials before any of the potential candidates is ready for validation and subsequent clinical application.
